Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 12;28(6):1288–1296. doi: 10.1038/s41591-022-01815-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 1 — A total of 62 volunteers without and with HIV were screened for study participation. In individuals without HIV, PGDM1400 was sequentially administered alone or followed by PGT121 in a single IV infusion at increasing doses of 3 mg/kg (Groups 1A and 2A), 10 mg/kg (Groups 1B and 2B), or 30 mg/kg (Groups 1C and 2C) for each bNAb. Viremic participants with HIV (Group 3) received a single IV dose of PGDM1400, PGT121 and VRC07-523LS at 20 mg/kg each (Group 3A) or a single dose of PGDM1400 and PGT121 at 30 mg/kg each (Group 3B). Of a total of 62 subjects screened, 24 participants without HIV and 5 participants with HIV were enrolled. Of the 29 participants enrolled, 26 completed the study on the planned schedule, and three terminated the study early (one Group 1B participant and one Group 3A participant were lost to follow-up and one Group 1C participant moved out of the area). However, no participants were excluded from the safety analyses as all participants had accrued follow-up time after IP administration.